title: Efficacy of rituximab in acquired factor XIII inhibitor after arterial rFVIIa-induced thrombosis.
authors.forename: F
authors.initials: F
authors.lastname: Ngo Sack
authors.forename: H
authors.initials: H
authors.lastname: Galinat
authors.forename: P-Y
authors.initials: PY
authors.lastname: Egreteau
authors.forename: L M
authors.initials: LM
authors.lastname: Mollard
authors.forename: H
authors.initials: H
authors.lastname: Fortin
authors.forename: C
authors.initials: C
authors.lastname: Berthou
authors.forename: J F
authors.initials: JF
authors.lastname: Abgrall
authors.forename: B
authors.initials: B
authors.lastname: Pan-Petesch
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood; D003029:Coagulants / Q000009:adverse effects*; D015942:Factor VIIa / Q000009:adverse effects*; D005177:Factor XIII Deficiency / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects; D000069283:Rituximab; D013927:Thrombosis / Q000139:chemically induced / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D019774:Blood Coagulation Factor Inhibitors; D003029:Coagulants; D007155:Immunologic Factors; D011994:Recombinant Proteins; D000069283:Rituximab; C103587:recombinant FVIIa; D015942:Factor VIIa